Cardiovascular disease (CVD) represents the number one and leading cause of death globally, and the majority of CVD is caused by atherosclerosis. Atherosclerosis is a systemic disease that leads to myocardial infarction, stroke and lower limb ischemia. Pathological studies have given insight to development of atherosclerosis and the importance of local plaque vulnerability and cardiovascular events. Due to the burden of cardiovascular disease, identification of the individual patient at risk for cardiovascular events and treatment stratification is needed. Furthermore, efforts at primary prevention for major risk sources and secondary prevention of recurrence are very important. For example, following stroke due to carotid artery stenosis, the likelihood of recurrence is relatively high (up to 10% for early embolic recurrence) but currently we have no options to predict who will and who will not suffer a secondary event. Although large series of patients have been reported in literature, some clinical aspects of the natural course of the disease are still poorly defined, creating doubts how to select the patient that will benefit from revascularization considering perioperative morbidity from the procedure itself.
